• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer.

作者信息

Lin Ching-Yu, Chuu Chih-Pin

机构信息

Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Miaoli.

PhD Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University, Taipei.

出版信息

Transl Androl Urol. 2020 Apr;9(2):837-839. doi: 10.21037/tau.2020.03.24.

DOI:10.21037/tau.2020.03.24
PMID:32420195
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7215030/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c76/7215030/fddc3b065471/tau-09-02-837-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c76/7215030/fddc3b065471/tau-09-02-837-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c76/7215030/fddc3b065471/tau-09-02-837-f1.jpg

相似文献

1
New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer.新的分类可能有助于为难治性去势抵抗性前列腺癌开发靶向治疗方法。
Transl Androl Urol. 2020 Apr;9(2):837-839. doi: 10.21037/tau.2020.03.24.
2
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.局部晚期和转移性前列腺癌的系统治疗进展：精准肿瘤学时代下转移性去势抵抗性前列腺癌的管理。
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
3
The hallmarks of castration-resistant prostate cancers.去势抵抗性前列腺癌的特征。
Cancer Treat Rev. 2015 Jul;41(7):588-97. doi: 10.1016/j.ctrv.2015.05.003. Epub 2015 May 9.
4
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.前列腺特异性抗原对延迟联合雄激素阻断治疗的反应预测了去势抵抗性前列腺癌患者后续雌激素和多西他赛治疗后的生存。
BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.
5
Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.针对去势抵抗性前列腺癌成骨转移的骨微环境靶向调控治疗
Expert Opin Investig Drugs. 2013 Nov;22(11):1385-400. doi: 10.1517/13543784.2013.824422. Epub 2013 Sep 12.
6
Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.口服/节拍式环磷酰胺为基础的化疗作为去势抵抗性前列腺癌患者的选择：文献综述。
Cancer Treat Rev. 2011 Oct;37(6):444-55. doi: 10.1016/j.ctrv.2010.12.006. Epub 2011 Jan 28.
7
Current therapeutic options in metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌的现有治疗选择。
Semin Oncol. 2018 Oct;45(5-6):303-315. doi: 10.1053/j.seminoncol.2018.10.001. Epub 2018 Oct 30.
8
Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.转移性去势抵抗性前列腺癌治疗的新兴及二线疗法：澳大利亚视角
Asia Pac J Clin Oncol. 2012 Mar;8(1):31-42. doi: 10.1111/j.1743-7563.2011.01506.x.
9
Novel agents for castration-resistant prostate cancer: Early experience and beyond.去势抵抗性前列腺癌的新型药物：早期经验及其他
Int J Urol. 2016 Feb;23(2):114-21. doi: 10.1111/iju.12907. Epub 2015 Aug 27.
10
Advances in systemic therapies for metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌全身治疗的进展
Future Oncol. 2014 Nov;10(14):2213-26. doi: 10.2217/fon.14.128.

引用本文的文献

1
Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer.简而言之：前列腺癌中的信号通路——从发病机制到治疗意义
Ann Med. 2025 Dec;57(1):2474175. doi: 10.1080/07853890.2025.2474175. Epub 2025 May 15.
2
Inflammation induced by lipopolysaccharide advanced androgen receptor expression and epithelial-mesenchymal transition progress in prostatitis and prostate cancer.脂多糖诱导的炎症促进了前列腺炎和前列腺癌中雄激素受体的表达以及上皮-间质转化进程。
Transl Androl Urol. 2021 Nov;10(11):4275-4287. doi: 10.21037/tau-21-964.
3
Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management.

本文引用的文献

1
Caffeic acid phenethyl ester suppresses androgen receptor signaling and stability via inhibition of phosphorylation on Ser81 and Ser213.阿魏酸苯乙酯通过抑制丝氨酸 81 和丝氨酸 213 的磷酸化来抑制雄激素受体信号转导和稳定性。
Cell Commun Signal. 2019 Aug 20;17(1):100. doi: 10.1186/s12964-019-0404-9.
2
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.分子谱分析对治疗抵抗的转移性去势抵抗性前列腺癌的多种表型进行分层。
J Clin Invest. 2019 Jul 30;129(10):4492-4505. doi: 10.1172/JCI128212.
3
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
不断演变的去势抵抗和前列腺特异性膜抗原表达：对患者管理的影响
Cancers (Basel). 2021 Jul 16;13(14):3556. doi: 10.3390/cancers13143556.
恩杂鲁胺治疗去势抵抗性前列腺癌非转移性患者的疗效。
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
4
Cellular plasticity and the neuroendocrine phenotype in prostate cancer.前列腺癌中的细胞可塑性和神经内分泌表型。
Nat Rev Urol. 2018 May;15(5):271-286. doi: 10.1038/nrurol.2018.22. Epub 2018 Feb 20.
5
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.雄激素作为治疗雄激素受体阳性去势抵抗性前列腺癌的药物。
J Biomed Sci. 2011 Aug 23;18(1):63. doi: 10.1186/1423-0127-18-63.
6
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
7
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.III 类β-微管蛋白表达可预测前列腺肿瘤侵袭性和患者对多西紫杉醇为基础的化疗的反应。
Cancer Res. 2010 Nov 15;70(22):9253-64. doi: 10.1158/0008-5472.CAN-10-1447. Epub 2010 Nov 2.
8
Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.(-)-表没食子儿茶素-3-没食子酸酯对LNCaP前列腺癌细胞不同进展阶段雄激素受体信号传导和前列腺特异性抗原表达的抑制作用
Cancer Lett. 2009 Mar 8;275(1):86-92. doi: 10.1016/j.canlet.2008.10.001. Epub 2008 Nov 1.
9
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.多西他赛与雌莫司汀对比米托蒽醌和泼尼松治疗晚期难治性前列腺癌的疗效
N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318.
10
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.多西他赛联合泼尼松或米托蒽醌联合泼尼松用于晚期前列腺癌治疗
N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720.